(Press-News.org) HOUSTON (Aug. 22, 2023) — The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute® (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatment regimens — specifically for adverse events arising from atherosclerosis.
Cardiovascular disease is the leading cause of death worldwide, with the Centers for Disease Control and Prevention (CDC) estimating that one person dies from CVD every 33 seconds in the United States, accounting for one in every five deaths in 2021.
CVD leads to heart attack, heart failure, and stroke, mainly caused by atherosclerosis — the thickening and hardening of arteries, which carry oxygen-rich blood from the heart to the rest of the body — due to plaque buildup. The plaques, formed by cholesterol deposits and other substances, cause arteries to become narrow, blocking blood flow. The consequent chronic inflammation eventually results in atherosclerotic plaque rupture or erosion, which is the leading cause of adverse cardiac events.
Conventional therapeutic approaches include the use of lipid-lowering statin drugs; however, many patients taking these medications still suffer life-threatening incidents often caused by residual inflammation risks. Indeed, many prominent clinical trials have established that atherosclerosis is an inflammatory disease and that lowering inflammation can reduce adverse cardiac events independent of statin drugs.
Targeting this lingering inflammation — even in patients currently receiving the best standards of care — can significantly benefit clinical outcomes.
"Given the sobering mortality statistics associated with heart disease, a novel therapy that could change disease trajectory and delay or prevent events associated with atherosclerotic cardiovascular disease would be a significant improvement to current treatment regimens," said Dr. Darren G. Woodside, Vice President for Research, Senior Investigator, and Director of the Flow Cytometry and Imaging Core at The Texas Heart Institute.
Apart from lipid-lowering approaches, current treatments for atherosclerosis primarily target risk factors associated with cardiovascular events after plaque rupture. In this project — funded under the NHLBI Catalyze Program — this new strategy will enable the suppression of white blood cell activation within atherosclerotic plaques beforehand by inhibiting the production of pro-inflammatory mediators like interleukin-1β (IL-1β).
This initiative may lead to starting points for drug development and help establish industry partnerships — similar to other programs that have recently arisen from THI scientists’ inventions — involving technologies invented by Dr. Woodside and co-principal investigator Dr. Ronald J. Biediger, Director of Medicinal Chemistry, and other members of the Molecular Cardiology Research Laboratories at The Texas Heart Institute.
Drs. Woodside and Biediger initiated a drug discovery and development program to target the molecular interactions between of a group of cell surface proteins called integrins and an intracellular protein termed Syk, which is important for producing IL-1β. Dr. Woodside’s team recently published a study in Frontiers in Immunology indicating that such an interaction between integrins and Syk can be inhibited by small molecule compounds. They foresee that those small molecule compounds can be developed to generate an innovative drug to mitigate residual inflammatory risk in cardiovascular patients — above and beyond the capability of statin drugs — improving patients’ cardiovascular health. The ideal future drug would be orally available, administered daily and have no significant adverse side effects.
"If successful, our approach would represent a first-in-class therapeutic, as no drugs marketed today take advantage of this specific strategy of targeting integrin signaling through Syk," said Dr. Woodside.
This research is supported by the NHLBI of the National Institutes of Health under Award Number: R61 HL168737. The NHLBI, one of the largest institutes and centers comprising the National Institutes of Health (NIH), “provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood disorders and enhance the health of all individuals so that they can live longer and more fulfilling lives.”
The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
###
About The Texas Heart Institute®
The Texas Heart Institute is an independent, nonprofit organization with the mission of “improving cardiovascular health today through trailblazing research, thought leadership, education, and patient care.” Located within the Texas Medical Center in Houston, Texas, and founded in 1962 by renowned cardiac surgeon Dr. Denton Cooley, The Texas Heart Institute performed the first successful heart transplant and total artificial heart implant in the United States. Since then, our physicians and surgeons have remained recognized as worldwide leaders in diagnosing and treating even the most complex cardiovascular conditions. Research programs at The Texas Heart Institute continue pushing cardiovascular science’s boundaries by translating laboratory discovery into patient care. The Texas Heart Institute has been ranked among the top cardiovascular centers in the United States by U.S. News & World Report for over 30 years. www.texasheart.org @texasheartinstitute
END
SAN ANTONIO (Aug. 22, 2023) — The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) and seven regional collaborators will leverage $46 million from the National Institutes of Health (NIH) over the next five to seven years to translate scientific discoveries into therapeutic benefits for human health and well-being.
A key focus will be reducing health disparities among Mexican Americans, active military personnel and veterans.
William L. Henrich, ...
The management of working capital — or a firm’s current assets minus its current liabilities — aids organizations in making efficient use of their existing assets and maximizing cash flow.
The relationship between efficient working capital management and firm performance can be complex due to globally dispersed supply chains, number of suppliers and product variety, and technological uncertainty, among other factors.
New research from the University of Notre Dame shows that information technology represents a critical investment that ...
BERLIN, Germany – Stealth BioTherapeutics, a front-runner in the world of mitochondrial medicine, is set to unveil its latest breakthroughs at the much-anticipated Targeting Mitochondria 2023 conference in Berlin this October.
Dr. David A. Brown, Vice President of Mitochondrial Research at Stealth BioTherapeutics, is slated to give an enlightening talk titled, “Translational insights from targeting mitochondria in rare diseases.” His presentation promises to provide insights into Stealth’s progress in clinical programs, with updates on their advancements in addressing rare mitochondrial diseases across several Phase 2/3 clinical trials. ...
Cellular solids are materials composed of many cells that have been packed together, such as a honeycomb. The shape of those cells largely determines the material’s mechanical properties, including its stiffness or strength. Bones, for instance, are filled with a natural material that enables them to be lightweight, but stiff and strong.
Inspired by bones and other cellular solids found in nature, humans have used the same concept ...
A University of Houston researcher is launching a new study to examine how elementary schools across Texas and Florida identify specific learning disabilities in students, with the goal of improving processes so children with significant academic difficulties can succeed.
Jeremy Miciak, research associate professor of psychology at the University of Houston’s Texas Institute for Measurement, Evaluation, and Statistics, was awarded a $1.7 million grant from the National Center for Special Education Research at the Institute of Education Sciences, the research arm ...
“To the best of our knowledge, this is the first study to have demonstrated the preventive effect of AF ablation on long-term AF-related cardiovascular events in very old patients with NVAF.”
BUFFALO, NY- August 22, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 15, entitled, “Cardiovascular events and death after catheter ablation in very old patients with nonvalvular ...
More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the world are searching for new effective substances. Researchers from the University of Bonn, the German Center for Infection Research (DZIF), Utrecht University (Netherlands), Northeastern University in Boston (USA) and the company NovoBiotic Pharmaceuticals in Cambridge (USA) now have discovered and deciphered the mode of action of a new antibiotic. Clovibactin is derived from ...
PHILADELPHIA—(August 22, 2023)—Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio. In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC. In evaluating EBVaGC’s epigenetics — the series of biological signals associated with the genome that determines whether a given gene is expressed — the Tempera lab ...
– By Alison Hatt
The prospect of a quantum internet, connecting quantum computers and capable of highly secure data transmission, is enticing, but making it poses a formidable challenge. Transporting quantum information requires working with individual photons rather than the light sources used in conventional fiber optic networks. To produce and manipulate individual photons, scientists are turning to quantum light emitters, also known as color centers. These atomic-scale defects in semiconductor materials can emit single photons of fixed wavelength or color and allow photons to interact with electron spin properties in controlled ways.
A team ...
Scientists and imaging specialists have teamed up to help save one of the world’s most endangered groups of animals: freshwater mussels. With funding provided by the U.S. Fish and Wildlife Service’s National Conservation Training Center, imaging experts will create 3D shell models based on specimens from the Florida Museum of Natural History and the Smithsonian Institution’s National Museum of Natural History.
Once complete, the models will be available online for free to educate the public about these amazing yet little-known creatures that ...
